

Tetrahedron 56 (2000) 5213-5219

## Synthesis of New Unexpected Stable Mixed Alkanoic, Phosphonic and Sulphonic (Dichloromethylene)bisphosphonic Anhydride Esters

M. J. Ahlmark\* and J. J. Vepsäläinen

Department of Chemistry, University of Kuopio, P.O. Box 1627, 70211 Kuopio, Finland

Received 29 March 1999; revised 25 April 1999; accepted 8 May 2000

**Abstract**—New mixed alkanoic, phosphonic and sulphonic (dichloromethylene)bisphosphonic anhydride esters  $[(RO)_2P(O)CCl_2-P(O)(OX)(O^Z^+), (RO)_2P(O)CCl_2P(O)(OX)(OR) and (Z^+O^-)(RO)P(O)CCl_2P(O)(OX)(O^Z^+); X=C(O)R, P(O)(OR)_2, SO_2Me; R=CH_3, C_6H_5, CH(CH_3)_2, (CH_2)_5CH_3; Z=ammonium, Na^+, K^+)]$  were selectively synthesised, and characterised by NMR spectroscopy. These new compounds are stable and bear potential bioreversible bisphosphonate protecting groups. © 2000 Elsevier Science Ltd. All rights reserved.

Clodronate (Cl<sub>2</sub>MBP) 1 and other methylenebisphosphonates (MBP) are analogues of pyrophosphate, but resistant to chemical and enzymatic hydrolysis.<sup>1</sup> These compounds are used in the treatment of diseases related to enhanced bone resorption such as osteoporosis, Paget's disease and tumor-induced hypercalcaemia.<sup>2–5</sup> Due to their high polarity and ionisation at physiological pH, MBPs possess limited oral bioavailability (1-5%),<sup>2,6</sup> which is likely attributed to their poor lipophilicity and charge, which in addition prevents the cellular uptake.<sup>2,7</sup> Furthermore, complexation of MBPs with divalent metal cations may reduce the absorption to zero.<sup>6–8</sup> This and the low bioavailability could be avoided by masking one or more ionisable groups by using the prodrug approach: a promoiety is linked to the functional group of a drug to form a prodrug, which should undergo chemical or enzymatic hydrolysis or both to regenerate the parent compound after absorption.<sup>9,10</sup> In many cases, neutral esters, simple esters or acyloxyalkyl esters, have been used as bioreversible promoities for polar compounds.10-13



Keywords: bisphosphonates; synthesis; mixed anhydrides.

Earlier, the selective synthesis of tetraalkyl,<sup>14,15</sup> partial alkyl<sup>16</sup> and amide esters<sup>17</sup> of clodronate have been reported. From these, simple esters were shown to be ineffective as prodrugs due to their stability towards aqueous and enzymatic hydrolysis.<sup>18</sup> It has been proposed that esters bearing a negative charge in close proximity to the site of action of esterases are poor prodrugs.<sup>19,20</sup> This could probably be avoided by using acyloxyalkyl esters, where the site of action of the esterase is separated from the charge or by using anhydrides, which were shown to be bioreversible despite of the presence of negative charge in close proximity.<sup>21</sup> However, the method described in a patent<sup>22</sup> for preparing tetra(acyloxyalkyl) esters was not successful in our hands.

Based on the bioreversibility of anhydrides<sup>21</sup> and difficulties in preparing acyloxyalkyl derivatives, we decided to study the synthesis of mixed anhydride esters 2-4 [X=C(O)R, P(O)(OR)<sub>2</sub>, SO<sub>2</sub>Me; R=CH<sub>3</sub>, C<sub>6</sub>H<sub>5</sub>, CH(CH<sub>3</sub>)<sub>2</sub>, (CH<sub>2</sub>)<sub>5</sub>CH<sub>3</sub>] using simple esters as models for acyloxyalkyl esters. In such compounds, potential bioreversible anhydride structures are present and it is possible to mask three or even four chargeable groups of Cl<sub>2</sub>MBP.

### **Results and Discussion**

We have recently described the synthesis and in vitro evaluation of P,P'-dianhydrides of  $Cl_2MBP$  **5** (R=CH<sub>3</sub>; (CH<sub>2</sub>)<sub>2</sub>CH<sub>3</sub>; C(CH<sub>3</sub>)<sub>3</sub>; C<sub>6</sub>H<sub>5</sub>), which were obtained selectively from tetrasodium clodronate **6** and acid anhydrides (Scheme 1).<sup>21</sup> Although anhydrides of etidronate [(H<sub>3</sub>C)(HO)C[P(O)(OH)(O<sup>-</sup>Na<sup>+</sup>)]<sub>2</sub>] were unstable under isolation, the dianhydrides of clodronate are stable and bioreversible. The obvious reason for the stability in water

<sup>\*</sup> Corresponding author. E-mail: marko.ahlmark@uku.fi



Scheme 1. (i) (RCO)<sub>2</sub>O.

(half-lives from 15 to 790 h, pH 7.4) is the electronegative chlorine atoms in the bridging carbon. However, this synthesis strategy suffers from limitations: only dianhydrides of clodronate were formed selectively; tri (7) or tetra anhydrides were not detected in the reaction mixture. Thus, in order to mask more than two charges we used partial esters of  $Cl_2MBP$  to produce selectively mixed anhydride esters of  $Cl_2MBP$ .

The strategy to prepare mixed anhydride esters of Cl<sub>2</sub>MBP is based on our previous studies<sup>23</sup> to prepare P,P-diesters in which sulphonic-anhydride structure was an intermediate. Following this approach we prepared compounds 2 and 3 depending on the counterion  $Z^+$ , which promotes the reaction on P'. In Scheme 2, the reaction between 8a-b and the reagent yielded selectively alkanoic, sulphonic and phosphonic anhydride esters of Cl<sub>2</sub>MBP (2a-f and 2h-j). For **8a** (R=Me, Z=Me<sup>+</sup>NBu<sub>3</sub>) 1-1.5 equiv. of the reagent was needed to complete the reaction, acylation and sulphonation were then easily achieved. These reactions occurred at room temperature, but when the mixture was heated at 60°C or under reflux, the reaction was complete in 1-2 h. After vacuum evaporation, the product was obtained quantitatively without need for purification, except in the case of 2c. The phosphorylation of 8a required 1 equiv. of freshly distilled phosphorochloridic acid dialkyl ester (R=Me, <sup>1</sup>Pr or Hex) under anhydrous reaction conditions, leading typically to a mixture of 8a, the reagent, by-products and 2d-fwith about 80-85% selectivity. These products are stable in cold water thus the synthesis impurities were removed by washing with cold water, lowering the yields of desired products. The same approach was used for **8b** ( $R=^{i}Pr$ ), but in this case increasing the amount of the reagents (1.5-2.0 equiv.) and heating the solvents under reflux for 2 h. After purification, the products (2h-j) were obtained with 60, 98 and 54% of the theoretical yield, respectively; 2i and 2j still containing impurities. If 8b is not the main impurity, the crude products can be extracted to the aqueous layer to gain higher purity. For example, 2i was extracted to the aqueous layer from the toluene layer and isolated with 97% yield and 96% purity.



Scheme 2. (i) ClC(O)R or  $ClP''(O)(OR)_2$  or  $ClSO_2Me$ ; (ii) NEt<sub>3</sub> and ClC(O)R or  $ClP''(O)(OR)_2$ .

Using the same method as above but adding a base in the reaction mixture, we found a remarkable change in the reaction for 8b. In this way uncharged anhydride esters were selectively observed if the counterion was <sup>i</sup>Pr<sup>+</sup>Pyridine. In Scheme 2, 3a-c were obtained after 8b was treated with triethylamine and benzoyl chloride or phosphorochloridic acid dialkyl ester at room temperature after 6 h stirring;  $3\mathbf{a}-\mathbf{c}$  are difficult to obtain otherwise, although  $(HO)(^{i}PrO)P(O)CCl_{2}P(O)(O^{i}Pr)_{2}$  reacted with phosphorochloridic acid dialkyl esters in the presence of  $K_2CO_3$ yielding 3d-e. The same method for  $(MeO)_2P(O)CCl_2$ . P(O)(OMe)(OH) yielded 2 and traces of 3, and compound 2g was synthesised in this manner. Without base no acylation or phosphorylation was observed for (MeO)<sub>2</sub>P(O)CCl<sub>2</sub>P(O)(OMe)(OH), but in the case of  $(HO)(^{i}PrO)P(O)CCl_{2}P(O)(O^{i}Pr)_{2}$  the reaction succeeded in some extent with phosphorochloridic acid dialkyl esters. Efforts to synthesise 3, where R=Me, using 8a as starting material and the procedure used for 8b, failed resulting in  $(MeO)_2P(O)Cl_2CP(O)(O^-Z^+)(OX)$ . The difference in reaction between **8a** and **8b** is probably caused by the catalytic effect from the formation of 1-propene. Indeed, in the case of **8b** the <sup>1</sup>H NMR spectra (at low temperature) confirmed the production of propene during the reaction. Efforts to synthesise mixed dianhydride esters of Cl<sub>2</sub>MBP failed. We used  $(Z^+O^-)(MeO)P(O)CCl_2P(O)(OMe)(O^-Z^+)$  (Z=H or ammonium) as a starting material and acetyl chloride or acetic anhydride as a reagent, but no desired product was obtained under any conditions from room temperature to heating under reflux.

Earlier we described the use of piperidine as a dealkylating agent for diester **9** to selectively form monoester derivative.<sup>24</sup> We used this derivative and acetic anhydride to selectively form mixed anhydride ester **4**. In Scheme 3, the P,P-diester **9** was first treated with an excess of piperidine in the presence of water to remove<sup>24</sup> selectively one of the methyl groups. After evaporation in vacuo, the residue was treated with a large excess of acetic anhydride. Due to the piperidinium exchange between P and P', the diester **9** was P' acylated. This was verified from the <sup>1</sup>H and <sup>31</sup>P NMR spectra: the <sup>1</sup>H spectrum showed a doublet at 2.22 ppm with 1 Hz coupling constant and the <sup>1</sup>H coupled <sup>31</sup>P spectrum



Scheme 3. (i) Water/piperidine; (ii) (CH<sub>3</sub>CO)<sub>2</sub>O.

**Table 1.** The yields, <sup>31</sup>P NMR shifts and <sup>2</sup> $J_{PP}$  constants for mixed anhydride esters of Cl<sub>2</sub>MBP

Compound	R	Х	Z	$\delta_{ m P}$	$\delta_{\mathrm{P}'}$	$\delta_{\mathrm{P}''}$	$^{2}J_{\mathrm{PP}^{\prime}}$	${}^{2}J_{\mathbf{P}'\mathbf{P}''}$	Yield (%)
8a	Me	_	Me <sup>+</sup> NBu <sub>3</sub>	15.3	4.3	_	16.6	_	_
8b	<sup>i</sup> Pr	_	<sup>i</sup> Pr <sup>+</sup> Pyridine	11.1	3.3	_	19.9	_	_
2a	Me	C(O)CH <sub>3</sub>	Me <sup>+</sup> NBu <sub>3</sub>	14.15	-2.64	-	18.2	_	100
2b	Me	SO <sub>2</sub> Me	Me <sup>+</sup> NBu <sub>3</sub>	12.37	-3.29	-	21.1	_	100
2c	Me	$\tilde{C(O)C_6H_5}$	Me <sup>+</sup> NBu <sub>3</sub>	14.71	-1.06	-	18.3	_	81
2d	Me	$P(O)(OMe)_2$	Me <sup>+</sup> NBu <sub>3</sub>	14.17	-4.61	-10.04	20.1	27.7	43
2e	Me	$P(O)(O^{i}Pr)_{2}$	Me <sup>+</sup> NBu <sub>3</sub>	14.36	-4.90	-13.96	21.2	26.3	77
2f	Me	P(O)(OHex) <sub>2</sub>	Me <sup>+</sup> NBu <sub>3</sub>	14.44	-4.43	-12.10	21.2	26.7	37
2g	Me	$P(O)(OHex)_2$	K <sup>+</sup>	14.04	-3.27	-11.3	24.3	26.8	12
2h	<sup>i</sup> Pr	SO <sub>2</sub> Me	<sup>i</sup> Pr <sup>+</sup> Pyridine	8.27	-1.37	-	22.9	_	60
2i	<sup>i</sup> Pr	$P(O)(O^{i}Pr)_{2}$	<sup>i</sup> Pr <sup>+</sup> Pyridine	9.09	-3.91	-13.76	25.0	26.6	98
2j	<sup>i</sup> Pr	$P(O)(OHex)_2$	<sup>i</sup> Pr <sup>+</sup> Pyridine	9.35	-3.52	-11.79	25.5	26.3	54
3a	<sup>i</sup> Pr	C(O)C <sub>6</sub> H <sub>5</sub>	_	6.37	3.67	-	25.3	_	96
3b	<sup>i</sup> Pr	$P(O)(O^{i}Pr)_{2}$	_	6.32	-0.93	-14.55	25.7	28.9	100
3c	<sup>i</sup> Pr	$P(O)(OHex)_2$	_	6.23	-0.84	-12.78	25.7	30.2	81
3d	<sup>i</sup> Pr	$P(O)(OMe)_2$	_	6.10	-0.59	-10.78	25.6	29.7	48
3e	<sup>i</sup> Pr	SO <sub>2</sub> Me	_	5.61	0.66	-	25.1	_	32
4	-	$C(O)CH_3$	-	9.08	4.06	-	16.1	-	76

showed two patterns: a doublet of quartets at 9.08 ppm with a  ${}^{3}J_{\rm HP}$  constant of 10.4 Hz; a doublet at 4.06 ppm, but when resolution enhancement was used, a quartet was obtained with a  ${}^{4}J_{\rm PH}$  constant of 1 Hz. After 24 h of stirring of the mixture at room temperature, the acid-insoluble product 4 was easily collected as white solids from the solution. Other acid anhydrides, butyric or hexanoic anhydrides, formed a gel under the reaction conditions and no desired product was obtained.

Products were characterised by <sup>1</sup>H, <sup>31</sup>P and <sup>13</sup>C NMR spectroscopy, and ES-MS. NMR data is listed in the Experimental section and the <sup>31</sup>P chemical shifts are listed in Table 1. Some of the characteristic NMR features of these compounds are discussed below. Typically, the <sup>31</sup>P' signal for mixed anhydride esters migrates significantly upfield with respect to the starting material: the upfield shift is generally 4–9 ppm higher for the phosphorylated compounds. Also the  ${}^{2}J_{PP}$  constants were informative: the increase for the products in  ${}^{2}J_{PP'}$  was generally 1.6–5.8 Hz being higher for the phosphorylated compounds, for which the <sup>1</sup>H decoupled <sup>31</sup>P NMR spectra showed a triplet or doublet of doublets corresponding to P'. In addition, the formation of mixed sulphonic anhydrides was confirmed by the <sup>1</sup>H coupled <sup>31</sup>P NMR spectra: a <sup>31</sup>P' doublet of doublets was detected for uncharged 3e at 0.66; a <sup>31</sup>P' doublet was detected at -3.29 or -1.37 for charged **2b** and 2h, respectively. Strong evidence for the formation of alkanoic anhydrides was provided by <sup>1</sup>H decoupled <sup>13</sup>C NMR spectra, where the P–O– $C^{\alpha}$  shift for the carbonyl carbon appeared as a doublet with a  ${}^{2}J_{CP}$  constant between 8.8 and 10.4 Hz in the region 167–160 ppm.

### Conclusions

A selective and general method for the synthesis of mixed anhydride esters of  $Cl_2MBP$  has been developed. Starting the synthesis from triester **8** either P,P-diester-P'-anhydrides or P,P,P'-triester-P'-anhydride is obtained with good yields. The present mixed alkanoic, phosphonic and sulphonic (dichloromethylene)bisphosphonic anhydride esters are new compounds bearing potential enzyme-labile anhydride groups. Since simple esters of clodronate are not regenerated<sup>18</sup> to the parent drug, they are used here as models for acyloxyalkyl derivatives, which are potential enzyme-labile groups.<sup>20</sup> Thus, it is expected that mixed anhydride esters have a broad application in the prodrug approach.

### **Experimental**

### General

All solvents and reagents were high-purity-grade materials and used without further purification except acetic anhydride, acetyl chloride, methanesulphonyl chloride and phosphorochloridic acid dialkyl esters reagents, which were distilled before use. NMR spectra were recorded on a Bruker AM 400 spectrometer using TMS or TSP as an internal standard for <sup>1</sup>H and <sup>13</sup>C measurements and 85%  $H_3PO_4$  as an external standard for <sup>31</sup>P measurements. The letter 'J' indicates normal 3JHH couplings and all J values are given in Hz. ES mass spectra was recorded using a Finnigan quadrupole ion trap mass spectrometer. HRMS spectra were recorded using Micromass LCT equipment and Bruker BioAPEX 47e FTICR mass spectrometer. The purity of products was >95% unless stated otherwise. Phosphorochloridic acid dialkyl esters were prepared from phosphorus trichloride.<sup>24</sup> Synthesis and characterisation of bisphosphonate starting materials 8a-b and 9 have been reported earlier.<sup>16,23</sup>

# General procedure for the synthesis of Cl<sub>2</sub>MBP anhydride esters (2a-f)

Acetonitrile (3.0 ml), **8a** and acetyl chloride (1.5 equiv.), benzoyl chloride (1.05 equiv.), methanesulphonyl chloride (1.25 equiv.) or phosphorochloridic acid dialkyl ester (1.0 equiv.) were mixed and heated at 60°C (**2a**) for 1 h or under reflux for 45 min (**2d**–**e**), 1 h (**2b**), 2 h (**2c**) or 4 h (**2f**), and then evaporated to dryness in vacuo. The residue of **2c**–**f** was redissolved in 4.0 ml cold CH<sub>2</sub>Cl<sub>2</sub> and washed once (twice for **2d**) with 0.5 ml cold saturated aq. NaCl (**2c**–**e**) or 0.5 ml cold saturated aq. NaHCO<sub>3</sub> (**2f**). A centrifuge was used to facilitate the decantation. The organic phase was evaporated to dryness in vacuo.

**Tributyl(methyl)ammonium** *O*-acetyl[(dimethoxyphosphoryl)dichloromethyl]phosphonate (2a). Prepared from **8a** (200 mg) to give **2a** (213 mg, 100%) as yellowish oil;  $\nu$ (KBr) 3417, 2964, 2291, 1751, 1465, 1266;  $\delta_{\rm H}$  (400.1 MHz, CDCl<sub>3</sub>) 3.99 (6H, d,  ${}^{3}J_{\rm HP}$ =9.0 Hz, OMe), 3.36 (6H, m,  ${}^{+}NCH_{2}$ ), 3.20 (3H, s,  ${}^{+}NCH_{3}$ ), 2.07 (3H, s, O<sub>2</sub>CCH<sub>3</sub>), 1.68 (6H, m,  ${}^{+}NCH_{2}CH_{2}$ ), 1.43 (6H, m,  $CH_{2}CH_{3}$ ), 0.99 (9H, t, J=7.2 Hz, CH<sub>2</sub>CH<sub>3</sub>);  $\delta_{\rm P}$  (162.0 MHz, CDCl<sub>3</sub>) 14.15 (d,  ${}^{2}J_{\rm PP'}$ =18.2 Hz), -2.64 (d);  $\delta_{\rm C}$  (100.6 MHz, CDCl<sub>3</sub>) 166.97 (d,  ${}^{2}J_{\rm CP}$ =9.4 Hz), 75.00 (dd,  ${}^{1}J_{\rm CP}$ =149.9 Hz,  ${}^{1}J_{\rm CP}$ =132.7 Hz), 61.26 (CH<sub>2</sub>), 55.96 (qd,  ${}^{2}J_{\rm CP}$ =6.8 Hz, CH<sub>3</sub>), 48.74 (CH<sub>3</sub>), 24.25 (CH<sub>2</sub>), 19.65 (CH<sub>2</sub>), 13.70 (CH<sub>3</sub>); ES-MS (C<sub>5</sub>H<sub>9</sub>Cl<sub>2</sub>O<sub>7</sub>P<sub>2</sub>) m/z 312.9 [M-MeNBu<sub>3</sub>]<sup>-</sup>; HRMS: [MH-MeNBu<sub>3</sub>+NH<sub>4</sub>]<sup>+</sup>, found 331.9636. C<sub>5</sub>H<sub>14</sub>NO<sub>7</sub>P<sub>2</sub>Cl<sub>2</sub> required 331.9623.

**Tributyl(methyl)ammonium** *O*-methylsulphonyl[(dimethoxyphosphoryl)dichloromethyl]phosphonate (2b). Prepared from **8a** (240 mg) to give **2b** (272 mg, 100%) as yellowish oil;  $\nu$ (KBr) 3427, 2965, 2253, 1464, 1263, 1180;  $\delta_{\rm H}$  (400.1 MHz, CDCl<sub>3</sub>) 4.00 (6H, d,  ${}^{3}J_{\rm HP}$ =10.7 Hz, OMe), 3.36 (3H, s, MeS), 3.31 (6H, m,  ${}^{+}$ NCH<sub>2</sub>), 3.14 (3H, s,  ${}^{+}$ NCH<sub>3</sub>), 1.68 (6H, m,  ${}^{+}$ NCH<sub>2</sub>CH<sub>2</sub>), 1.43 (6H, m, CH<sub>2</sub>CH<sub>3</sub>), 1.00 (9H, t, *J*=7.3 Hz, CH<sub>2</sub>CH<sub>3</sub>);  $\delta_{\rm P}$  (162.0 MHz, CDCl<sub>3</sub>) 12.37 (d,  ${}^{2}J_{\rm PP'}$ =21.1 Hz), -3.29 (d);  $\delta_{\rm C}$  (100.6 MHz, CDCl<sub>3</sub>) 73.62 (dd,  ${}^{1}J_{\rm CP}$ =151.54 Hz,  ${}^{1}J_{\rm CP}$ =142.7 Hz), 61.39 (CH<sub>2</sub>), 56.34 (d,  ${}^{2}J_{\rm CP}$ =7.0 Hz, CH<sub>3</sub>), 48.75 (CH<sub>3</sub>), 39.72 (CH<sub>3</sub>), 24.21 (CH<sub>2</sub>), 19.63 (CH<sub>2</sub>), 13.68 (CH<sub>3</sub>); ES-MS (C<sub>4</sub>H<sub>9</sub>Cl<sub>2</sub>O<sub>8</sub>P<sub>2</sub>S) 348.8 *m*/z [M-MeNBu<sub>3</sub>]<sup>-</sup>; HRMS: [MH-MeNBu<sub>3</sub>+NH<sub>4</sub>]<sup>+</sup>, found 367.9314. C<sub>4</sub>H<sub>14</sub>NO<sub>8</sub>P<sub>2</sub>SCl<sub>2</sub> required 367.9292.

**Tributyl(methyl)ammonium** *O*-benzoylyl[(dimethoxyphosphoryl)dichloromethyl]phosphonate (2c). Prepared from **8a** (100 mg) to give **2c** (96 mg, 81%) as yellowish oil;  $\nu$ (KBr) 3419, 2961, 1717, 1452, 1266;  $\delta_{\rm H}$ (400.1 MHz, CDCl<sub>3</sub>) 8.18 (2H, m, Ph), 7.53 (1H, m, Ph), 7.42 (2H, m, Ph), 3.99 (6H, d,  ${}^{3}J_{\rm HP}$ =10.7 Hz, OMe), 3.41 (6H, bs,  ${}^{+}NCH_{2}$ ), 3.32 (3H, s,  ${}^{+}NCH_{3}$ ), 1.67 (6H, bs,  ${}^{+}NCH_{2}CH_{2}$ ), 1.42 (6H, m,  $CH_{2}CH_{3}$ ), 0.98 (9H, t, J=7.1 Hz,  $CH_{2}CH_{3}$ );  $\delta_{\rm P}$  (162.0 MHz, CDCl<sub>3</sub>) 14.71 (d,  ${}^{2}J_{\rm PP'}$ =18.3 Hz), -1.06 (d);  $\delta_{\rm C}$  (100.6 MHz, CDCl<sub>3</sub>) 162.86 (d,  ${}^{2}J_{\rm CP}$ =8.8 Hz), 132.96 (CH), 130.94 (d,  ${}^{3}J_{\rm CP}$ = 5.4 Hz, C), 130.59 (CH), 128.24 (CH), 74.72 (dd,  ${}^{1}J_{\rm CP}$ = 150.8 Hz,  ${}^{1}J_{\rm CP}$ =135.3 Hz), 61.22 (CH<sub>2</sub>), 55.96 (d,  ${}^{2}J_{\rm CP}$ = 3.2 Hz, CH<sub>3</sub>), 48.98 (CH<sub>3</sub>), 24.34 (CH<sub>2</sub>), 19.69 (CH<sub>2</sub>), 13.72 (CH<sub>3</sub>); ES-MS (C<sub>10</sub>H<sub>11</sub>Cl<sub>2</sub>O<sub>7</sub>P<sub>2</sub>) 375.0 *m*/z [M-MeNBu<sub>3</sub>]<sup>-</sup>; HRMS: [MH-MeNBu<sub>3</sub>+NH<sub>4</sub>]<sup>+</sup>, found 393.9789. C<sub>10</sub>H<sub>16</sub>NO<sub>7</sub>P<sub>2</sub>Cl<sub>2</sub> required 393.9779.

**Tributyl(methyl)ammonium** *O*-dimethoxyphosphoryl-[(dimethoxyphosphoryl)dichloromethyl]phosphonate (2d). Prepared from 8a (100 mg) to give 2d (52 mg, 43%) as yellowish oil with 94% purity;  $\nu$ (KBr) 3427, 2963, 2185, 1464, 1269;  $\delta_{\rm H}$  (400.1 MHz, CDCl<sub>3</sub>) 4.00 (6H, d,  ${}^{3}J_{\rm HP}$ = 10.6 Hz, OMe), 3.87 (6H, d,  ${}^{3}J_{\rm HP}$ =11.6 Hz, OMe), 3.36 (6H, m,  ${}^{+}$ NCH<sub>2</sub>), 3.24 (3H, s,  ${}^{+}$ NCH<sub>3</sub>), 1.67 (6H, m,  ${}^{+}$ NCH<sub>2</sub>CH<sub>2</sub>), 1.44 (6H, m, CH<sub>2</sub>CH<sub>3</sub>), 1.00 (9H, t, *J*= 7.2 Hz, CH<sub>2</sub>CH<sub>3</sub>);  $\delta_{\rm P}$  (162.0 MHz, CDCl<sub>3</sub>) 14.17 (d,  ${}^{2}J_{\rm PP'}$ =20.1 Hz), -4.61 (dd), -10.04 (d,  ${}^{2}J_{\rm PP''}$ =27.7 Hz);  $δ_{\rm C}$  (100.6 MHz, CDCl<sub>3</sub>) 74.60 (ddd, <sup>1</sup>*J*<sub>CP</sub>=150.2 Hz, <sup>1</sup>*J*<sub>CP</sub>=137.5 Hz, <sup>3</sup>*J*<sub>CP</sub>=6.2 Hz), 61.26 (CH<sub>2</sub>), 56.04 (d, <sup>2</sup>*J*<sub>CP</sub>=6.7 Hz, CH<sub>3</sub>), 54.69 (d, <sup>2</sup>*J*<sub>CP</sub>=6.0 Hz, CH<sub>3</sub>), 48.97 (CH<sub>3</sub>), 24.30 (CH<sub>2</sub>), 19.69 (CH<sub>2</sub>), 13.73 (CH<sub>3</sub>); ES-MS (C<sub>5</sub>H<sub>12</sub>Cl<sub>2</sub>O<sub>9</sub>P<sub>3</sub>) 379.2 *m*/*z* [M-MeNBu<sub>3</sub>]<sup>-</sup>; HRMS: [MH-MeNBu<sub>3</sub>+NH<sub>4</sub>]<sup>+</sup>, found 397.9509. C<sub>5</sub>H<sub>17</sub>NO<sub>9</sub>P<sub>3</sub>Cl<sub>2</sub> required 397.9493.

**Tributyl(methyl)ammonium** *O*-di(1-methylethoxy)phosphoryl[(dimethoxyphosphoryl)dichloromethyl]phosphonate (2e). Prepared from 8a (100 mg) to give 2e (101 mg, 77%) as yellowish oil with 94% purity; ν(KBr) 3419, 2966, 2253, 1466, 1286;  $\delta_{\rm H}$  (400.1 MHz, CDCl<sub>3</sub>) 4.83 (2H, m, CH), 4.00 (6H, d,  ${}^{3}J_{\rm HP}$ =10.7 Hz, OMe), 3.41 (6H, m,  ${}^{+}NCH_{2}$ ), 3.29 (3H, s,  ${}^{+}NCH_{3}$ ), 1.68 (6H, m,  ${}^{+}NCH_{2}CH_{2}$ ), 1.44 (6H, m, CH<sub>2</sub>CH<sub>3</sub>), 1.35 (12H, d, *J*=6.1 Hz, CH<sub>3</sub>), 1.00 (9H, t, *J*=7.27 Hz, CH<sub>2</sub>CH<sub>3</sub>);  $\delta_{\rm P}$  (162.0 MHz, CDCl<sub>3</sub>) 14.36 (d,  ${}^{2}J_{\rm PP'}$ =21.2 Hz), -4.90 (dd), -13.96 (d,  ${}^{2}J_{\rm PP''}$ =26.3 Hz);  $\delta_{\rm C}$  (100.6 MHz, CDCl<sub>3</sub>) 74.72 (dd,  ${}^{1}J_{\rm CP}$ =150.6 Hz,  ${}^{1}J_{\rm CP}$ =137.2 Hz), 72.53 (d,  ${}^{2}J_{\rm CP}$ =5.9 Hz, CH), 61.26 (CH<sub>2</sub>), 56.03 (d,  ${}^{2}J_{\rm CP}$ =5.4 Hz, CH<sub>3</sub>), 23.60 (d,  ${}^{3}J_{\rm CP}$ =5.0 Hz, CH<sub>3</sub>), 19.71 (CH<sub>2</sub>), 13.73 (CH<sub>3</sub>); ES-MS (C<sub>9</sub>H<sub>20</sub>Cl<sub>2</sub>O<sub>9</sub>P<sub>3</sub>) 435.0 *m*/*z* [M-MeNBu<sub>3</sub>]<sup>-</sup>; HRMS: [MH<sub>2</sub>-MeNBu<sub>3</sub>]<sup>+</sup>, found 436.9883. C<sub>9</sub>H<sub>22</sub>O<sub>9</sub>P<sub>3</sub>Cl<sub>2</sub> required 436.9854.

Tributyl(methyl)ammonium O-dihexyloxyphosphoryl-[(dimethoxyphosphoryl)dichloromethyl]phosphonate (2f). Prepared from 8a (50 mg) to give 2f (27 mg, 37%) as yellowish oil; [Found: C, 42.94; H, 8.10; N 1.74. C<sub>28</sub>H<sub>62</sub>Cl<sub>2</sub>NO<sub>9</sub>P<sub>3</sub>×4H<sub>2</sub>O requires C, 42.43; H, 8.90; N 1.77%];  $\nu$ (KBr) 3423, 2962, 2331, 1466, 1289;  $\delta_{\rm H}$ (400.1 MHz, CDCl<sub>3</sub>) 4.18 (4H, m, OCH<sub>2</sub>), 4.00 (6H, d,  ${}^{3}J_{\rm HP}$ =10.8 Hz, OMe), 3.35 (6H, m,  ${}^{+}NCH_{2}$ ), 3.25 (3H, s, <sup>+</sup>NCH<sub>3</sub>), 1.60–1.70 (10H, m, <sup>+</sup>NCH<sub>2</sub>CH<sub>2</sub>, OCH<sub>2</sub>CH<sub>2</sub>), 1.44  $(6H, m, {}^{+}N(CH_2)_2CH_2), 1.36 (4H, m, O(CH_2)_2CH_2), 1.20-$ 1.30 (8H, m,  $O(CH_2)_3CH_2CH_2$ ), 1.00 (9H, t, J=7.2 Hz, <sup>+</sup>N(CH<sub>2</sub>)<sub>3</sub>CH<sub>3</sub>), 0.87 (6H, t, J=6.4 Hz, O(CH<sub>2</sub>)<sub>5</sub>CH<sub>3</sub>);  $\delta_{\rm P}$ (162.0 MHz, CDCl<sub>3</sub>) 14.44 (d,  ${}^{2}J_{PP'}=21.2$  Hz), -4.43 (dd), -12.10 (d,  ${}^{2}J_{P'P''}=26.7$  Hz);  $\delta_{C}$  (100.6 MHz, CDCl<sub>3</sub>) (dd),  $^{12.10}$  (d,  $^{13}_{PP}$ )  $^{-20.7}$  Hz),  $^{02}_{C}$  (100.5 MHz), CEC(3) 74.51 (dd,  $^{13}_{CP}$ =151.1 Hz,  $^{13}_{CP}$ =136.4 Hz), 68.15 (d,  $^{23}_{CP}$ =6.4 Hz, CH<sub>2</sub>), 61.22 (CH<sub>2</sub>), 56.04 (d,  $^{23}_{CP}$ =7.3 Hz, CH<sub>3</sub>), 49.21 (CH<sub>2</sub>), 31.46 (CH<sub>2</sub>), 30.25 (d,  $^{33}_{CP}$ =7.8 Hz, CH<sub>2</sub>), 25.21 (CH<sub>2</sub>), 24.33 (CH<sub>2</sub>), 22.58 (CH<sub>2</sub>), 19.71 14.03 13.74  $(CH_2),$  $(CH_3),$ (CH<sub>3</sub>); ES-MS  $(C_{15}H_{32}Cl_2O_9P_3)$  519.3 m/z [M-MeNBu<sub>3</sub>]<sup>-</sup>; HRMS:  $[MH_2-MeNBu_3]^+$ , found 521.0758.  $C_{15}H_{34}O_{9}P_{3}Cl_{2}$ required 521.0793.

# General procedure for the synthesis of Cl<sub>2</sub>MBP anhydride esters (2h-j)

Acetonitrile (3.0 ml), **8b** and sulphonyl chloride (1.5 equiv.) or phosphorochloridic acid dialkyl ester (2.0 equiv.) were mixed and heated under reflux for 2 h, and then evaporated to dryness in vacuo. The residue was redissolved in 10 ml (**2h**) or 4.0 ml (**2i**) cold  $CH_2Cl_2$  or 2.0 ml cold toluene (**2j**), and washed once with 1.0 ml cold water (**2h**) or twice with 2.0 ml cold water (**2j**) or once with 0.5 ml cold saturated aq. NaCl (**2i**). A centrifuge was used to facilitate the decantation. The organic phase was evaporated to dryness in vacuo.

*N*-(1-Methylethyl)pyridinium *O*-methylsulphonyl[(di-1methylethoxyphosphoryl)dichloromethyl]phosphonate (2h). Prepared from 8b (200 mg) to give 2h (128 mg, 60%) as yellowish oil; ν(KBr) 3434, 2983, 1630, 1484;  $\delta_{\rm H}$ (400.1 MHz, CDCl<sub>3</sub>) 9.33 (2H, bs, pyridinium), 8.44 (1H, bs, pyridinium) 8.21 (2H, bs, pyridinium), 5.28 (1H, m, <sup>+</sup>NCH), 4.97 (2H, m, OCH), 3.36 (3H, s, SCH<sub>3</sub>), 1.70 (6H, d, *J*=6.3 Hz, <sup>+</sup>NCH(*CH*<sub>3</sub>)<sub>2</sub>), 1.41 (12H, d, *J*=6.2 Hz, OCH(*CH*<sub>3</sub>)<sub>2</sub>);  $\delta_{\rm P}$  (162.0 MHz, CDCl<sub>3</sub>) 8.27 (d, <sup>2</sup>*J*<sub>PP</sub>/= 22.9 Hz), -1.37 (d);  $\delta_{\rm C}$  (100.6 MHz, CDCl<sub>3</sub>) 145.21 (CH), 143.55 (CH), 129.04 (CH), 75.10 (d, <sup>2</sup>*J*<sub>CP</sub>=7.5 Hz, CH), 74.37 (dd, <sup>1</sup>*J*<sub>CP</sub>=152.0 Hz, <sup>1</sup>*J*<sub>CP</sub>=138.8 Hz), 64.90 (CH), 39.65 (CH<sub>3</sub>), 23.62 (d, <sup>3</sup>*J*<sub>CP</sub>=3.0 Hz, CH<sub>3</sub>), 23.18 (CH<sub>3</sub>); HRMS: [MH<sub>2</sub>-<sup>i</sup>Pr<sup>+</sup>Pyridine]<sup>+</sup>, found 406.9693. C<sub>8</sub>H<sub>19</sub>O<sub>8</sub>P<sub>2</sub>SCl<sub>2</sub> required 406.9653.

*N*-(1-Methylethyl)pyridinium *O*-di(1-methylethoxy)phosphoryl[(di-1-methylethoxyphosphoryl)dichloromethyl]phosphonate (2i). Prepared from 8b (100 mg) to give 2i (123 mg, 98%) as yellowish oil with 92% purity;  $\nu$ (KBr) 3431, 2982, 2235, 1631, 1484;  $\delta_{\rm H}$  (400.1 MHz, CDCl<sub>3</sub>) 9.61 (2H, m, pyridinium), 8.42 (1H, m, pyridinium), 8.22 (2H, m, pyridinium), 5.47 (1H, m, CH), 4.99 (2H, m, CH), 4.84 (2H, m, CH), 1.73 (6H, d, *J*=6.6 Hz, CH<sub>3</sub>), 1.40 (12H, d, *J*=6.1 Hz, CH<sub>3</sub>), 1.34 (12H, d, *J*=6.1 Hz, CH<sub>3</sub>);  $\delta_{\rm P}$  (162.0 MHz, CDCl<sub>3</sub>) 9.09 (d, <sup>2</sup>*J*<sub>PP'</sub>=25.0 Hz), -3.91 (t), -13.76 (d, <sup>2</sup>*J*<sub>P'P''</sub> 26.6 Hz);  $\delta_{\rm C}$  (100.6 MHz, CDCl<sub>3</sub>) 145.20 (CH), 143.83 (CH), 129.11 (CH), 74.99 (ddd, <sup>1</sup>*J*<sub>CP</sub>=151.7 Hz, <sup>1</sup>*J*<sub>CP</sub>=139.9 Hz, <sup>3</sup>*J*<sub>CP</sub>=5.7 Hz), 74.60 (d, <sup>2</sup>*J*<sub>CP</sub>=7.4 Hz, CH), 72.84 (d, <sup>2</sup>*J*<sub>CP</sub>=6.2 Hz, CH), 64.63 (CH), 24.26 (d, <sup>3</sup>*J*<sub>CP</sub>=2.8 Hz, CH<sub>3</sub>), 23.74 (d, <sup>3</sup>*J*<sub>CP</sub>=4.7 Hz, CH<sub>3</sub>), 23.62 (d, <sup>3</sup>*J*<sub>CP</sub>=4.4 Hz, CH<sub>3</sub>), 23.57 (d, <sup>3</sup>*J*<sub>CP</sub>=3.6 Hz, CH<sub>3</sub>), 23.10 (CH<sub>3</sub>); ES-MS (C1<sub>3</sub>H<sub>28</sub>Cl<sub>2</sub>O<sub>9</sub>P<sub>3</sub>) 491.4 *m*/*z* [M<sup>-1</sup>Pr<sup>+</sup>Pyridine]<sup>-</sup>; HRMS: [MH<sub>2</sub>-<sup>1</sup>Pr<sup>+</sup>Pyridine]<sup>+</sup>, found 493.0450. C<sub>13</sub>H<sub>30</sub>O<sub>9</sub>P<sub>3</sub>Cl<sub>2</sub> required 493.0480.

N-(1-Methylethyl)pyridinium O-dihexyloxyphosphoryl-[(di-1-methylethoxyphosphoryl)dichloromethyl]phosphonate (2j). Prepared from 8b (250 mg) to give 2j (190 mg, 54%) as yellowish oil with 92% purity;  $\nu$ (KBr) 3435, 2959, 2253, 1483, 1386, 1291;  $\delta_{\rm H}$  (400.1 MHz, CDCl<sub>3</sub>) 9.48 (2H, m, pyridium), 8.37 (1H, m, pyridium), 8.23 (2H, m, pyridium), 5.43 (1H, bs, CH), 4.97 (2H, m, CH), 4.17 (4H, m), 1.69 (6H, d, *J*=6.1 Hz), 1.60–1.70 (4H, covered), 1.40 (6H, d, J=5.8 Hz), 1.39 (6H, d, J=6.1 Hz), 1.20-1.30 (8H, m), 1.3-1.4 (4H, covered), 0.87 (6H, t, J=6.7 Hz;  $\delta_{\text{P}}$  (162.0 MHz, CDCl<sub>3</sub>) 9.35 (d, <sup>2</sup> $J_{\text{PP}'}=$ 25.5 Hz), -3.52 (t), -11.79 (d,  ${}^{2}J_{P'P''}=26.3$  Hz);  $\delta_{C}$ (100.6 MHz, CDCl<sub>3</sub>) 144.69 (CH), 143.93 (CH), 128.99 (CH), 73.96 (ddd,  ${}^{1}J_{CP}$ =153.9 Hz,  ${}^{1}J_{CP}$ =148.8 Hz,  ${}^{3}J_{CP}$ = 5.2 Hz), 74.64 (d,  ${}^{2}J_{CP}$ =7.3 Hz, CH), 68.21 (d,  ${}^{2}J_{CP}$ = 6.4 Hz, CH<sub>2</sub>), 64.60 (CH<sub>2</sub>), 31.42 (CH<sub>2</sub>), 30.20 (d,  ${}^{3}J_{CP}$ =7.8 Hz, CH<sub>2</sub>), 25.19 (CH<sub>2</sub>), 23.63 (d,  ${}^{3}J_{CP}$ =6.4 Hz, (CH<sub>3</sub>), 23.27 (CH<sub>3</sub>), 22.56 (CH<sub>2</sub>), 14.01 (CH<sub>3</sub>); ES-MS  $(C_{19}H_{40}Cl_2O_9P_3)$  575.7 m/z  $[M^{-1}Pr^{+}Pyridine]^{-}$ ; HRMS:  $[MH_2 - {}^{1}Pr^{+}Pyridine]^{+}$ , found 577.1409.  $C_{19}H_{42}O_9P_3Cl_2$ required 577.1419.

### General procedure for the synthesis of Cl<sub>2</sub>MBP anhydride esters (3a-c)

Triethyl amine (1.5 equiv.) and bentzoyl chloride (1.5 equiv.), or phosphorochloridic acid dialkyl ester (1.2

equiv.) were diluted in acetonitrile (2.0 ml). Compound **8b**, diluted in acetonitrile (3.0 ml), was added dropwise to the solution and stirred at room temperature for 6 h under argon atmosphere. After evaporation of the mixture to dryness in vacuo, the residue was diluted in 10 ml (**3a**) or 4.0 ml (**3c**) cold toluene or 4.0 ml cold  $CH_2Cl_2$  (**3b**) and filtered if necessary. The filtrate was washed once with 1.0 ml cold water (**3a**) or 0.5 ml cold saturated aq. NaCl (**3b**) or 0.5 ml cold saturated aq. NaHCO<sub>3</sub> (**3c**). A centrifuge was used to facilitate decantation. The organic phase was evaporated to dryness in vacuo.

**1-Methylethyl** *O*-benzoyl[(di-1-methylethoxyphosphoryl)dichloromethyl]phosphonate (3a). Prepared from 8b (100 mg) to give 3a (93 mg, 96%) as orange oil;  $\nu$ (KBr) 2985, 2251, 1755, 1466, 1388, 1241;  $\delta_{\rm H}$  (400.1 MHz, CDCl<sub>3</sub>) 8.21 (2H, m, Ph), 7.65 (1H, m, Ph), 7.50 (2H, m, Ph), 5.32 (1H, m, CH), 5.02 (1H, m, CH), 5.01 (1H, m, CH), 1.52 (6H, d, *J*=6.2 Hz, CH<sub>3</sub>), 1.43 (12H, dd, CH<sub>3</sub>);  $\delta_{\rm P}$  (162.0 MHz, CDCl<sub>3</sub>) 6.37 (d, <sup>2</sup>*J*<sub>PP'</sub>=25.3 Hz), 3.67 (d);  $\delta_{\rm C}$  (100.6 MHz, CDCl<sub>3</sub>) 160.31 (d, <sup>2</sup>*J*<sub>CP</sub>=10.4 Hz), 134.75 (CH), 131.27 (CH), 128.34 (CH), 127.77 (d, <sup>3</sup>*J*<sub>CP</sub>=6.3 Hz, CH), 75.60 (d, <sup>2</sup>*J*<sub>CP</sub>=7.5 Hz, CH), 71.44 (dd, <sup>1</sup>*J*<sub>CP</sub>=162.3 Hz, <sup>1</sup>*J*<sub>CP</sub>=155.3 Hz), 24.32 (bs), 23.84 (d, <sup>3</sup>*J*<sub>CP</sub>=3.6 Hz, CH<sub>3</sub>), 23.52 (bs); HRMS: [M+Na]<sup>+</sup>, found 497.0431. C<sub>17</sub>H<sub>26</sub>O<sub>7</sub>P<sub>2</sub>Cl<sub>2</sub>Na required 497.0423.

**1-Methylethyl** *O*-di(1-methylethoxy)phosphoryl[(di-1-methylethoxyphosphoryl)dichloromethyl]phosphonate (3b). Prepared from 8b (100 mg) to give 3b (109 mg, 100%) as yellowish oil; [Found: C, 36.60; H, 6.87. C<sub>16</sub>H<sub>35</sub>Cl<sub>2</sub>O<sub>9</sub>P<sub>3</sub> requires C, 35.90; H, 6.59%];  $\nu$  (KBr) 3010, 2270, 1468, 1395, 1290;  $\delta_{\rm H}$  (400.1 MHz, CDCl<sub>3</sub>) 5.17 (1H, m, CH), 4.99 (1H, m, CH), 4.98 (1H, m, CH), 4.92 (1H, m, CH), 4.82 (1H, m, CH), 1.50 (3H, d, *J*=6.3 Hz, CH<sub>3</sub>), 1.47 (3H, d, *J*=6.3 Hz, CH<sub>3</sub>), 1.43 (12H, d, *J*=6.3 Hz, CH<sub>3</sub>), 1.40 (12H, d, *J*=6.4 Hz, CH<sub>3</sub>);  $\delta_{\rm P}$  (162.0 MHz, CDCl<sub>3</sub>) 6.32 (d, <sup>2</sup>*J*<sub>CP</sub>=7.4 Hz, CH), 75.65 (d, <sup>2</sup>*J*<sub>CP</sub>=7.4 Hz, CH), 75.74 (d, <sup>2</sup>*J*<sub>CP</sub>=6.0 Hz, CH), 74.65 (d, <sup>2</sup>*J*<sub>CP</sub>=6.2 Hz, CH), 71.46 (ddd, <sup>1</sup>*J*<sub>CP</sub>=165.9 Hz, <sup>1</sup>*J*<sub>CP</sub>=156.2 Hz, <sup>3</sup>*J*<sub>CP</sub>=4.7 Hz), 24.38 (d, <sup>3</sup>*J*<sub>CP</sub>=3.4 Hz, CH<sub>3</sub>), 23.69 (d, <sup>3</sup>*J*<sub>CP</sub>=5.1 Hz, CH<sub>3</sub>), 23.63 (d, <sup>3</sup>*J*<sub>CP</sub>=5.2 Hz, CH<sub>3</sub>), 23.47 (bs); HRMS: [M+Na]<sup>+</sup>, found 557.0760. C<sub>16</sub>H<sub>35</sub>O<sub>9</sub>P<sub>3</sub>Cl<sub>2</sub>Na required 557.0763.

1-Methylethyl O-dihexyloxyphosphoryl[(di-1-methylethoxyphosphoryl)dichloromethyl]phosphonate (**3c**). Prepared from **8b** (100 mg) to give **3c** (102 mg, 81%) as yellowish oil with 94% purity; [Found: C, 43.52; H, 7.58. C<sub>22</sub>H<sub>47</sub>Cl<sub>2</sub>O<sub>9</sub>P<sub>3</sub> requires C, 42.66; H, 7.65%]; ν (KBr) 2960, 2252, 1467, 1387, 1288;  $\delta_{\rm H}$  (400.1 MHz, CDCl<sub>3</sub>) 5.16 (1H, m, CH), 4.99 (1H, m, CH), 4.98 (1H, m, CH), 4.31-4.15 (4H, m, CH<sub>2</sub>), 1.72 (4H, m, CH<sub>2</sub>), 1.50 (3H, d, J=6.2 Hz, CH<sub>3</sub>), 1.47 (3H, d, J=6.2 Hz, CH<sub>3</sub>), 1.43 (12H, d, J=6.1 Hz, CH<sub>3</sub>), 1.50–1.35 (4H, covered, CH<sub>2</sub>), 1.30 (8H, m, CH<sub>2</sub>), 0.89 (6H, m, CH<sub>3</sub>);  $\delta_P$  (162.0 MHz, CDCl<sub>3</sub>) 6.23 (d,  $^{2}J_{\text{PP}'}$ =25.7 Hz), -0.84 (dd), -12.78 (d,  $^{2}J_{\text{P}'\text{P}''}$ =30.2 Hz);  $\delta_{\rm C}$  (100.6 MHz, CDCl<sub>3</sub>) 77.96 (d, <sup>2</sup>J<sub>CP</sub>=7.5 Hz, CH), 75.78 (d,  ${}^{2}J_{CP}$ =7.2 Hz, CH), 75.69 (d,  ${}^{2}J_{CP}$ =7.3 Hz, CH), 71.40 (dd,  ${}^{1}J_{CP}$ =165.6 Hz,  ${}^{1}J_{CP}$ =155.5 Hz,  ${}^{3}J_{CP}$ =4.6 Hz), 69.45 (d,  ${}^{2}J_{CP}$ =6.4 Hz, CH<sub>2</sub>), 69.35 (d,  ${}^{2}J_{CP}$ =6.7 Hz, CH<sub>2</sub>), 31.30 (CH<sub>2</sub>), 30.05 (d,  ${}^{3}J_{CP}$ =7.6 Hz, CH<sub>2</sub>), 25.03 (CH<sub>2</sub>), 24.34 (bs), 24.13 (d,  ${}^{3}J_{CP}$ =2.6 Hz, CH<sub>3</sub>), 23.45 (bs), 22.52 (CH<sub>2</sub>), 13.98 (CH<sub>3</sub>); ES-MS (C<sub>22</sub>H<sub>48</sub>Cl<sub>2</sub>O<sub>9</sub>P<sub>3</sub>) 619.0 *m/z* [MH]<sup>+</sup>; HRMS: [M+Na]<sup>+</sup>, found 641.1711. C<sub>22</sub>H<sub>47</sub>O<sub>9</sub>P<sub>3</sub>Cl<sub>2</sub>Na required 641.1702.

# General procedure for the synthesis of Cl<sub>2</sub>MBP anhydride esters (2g and 3d-e)

Anhydrous  $K_2CO_3$  [1.0 equiv. (2g), 2.5 equiv. (3d) or 1.5 equiv. (3e)], methane sulphonyl chloride (1.2 equiv.) or phosphorochloridic acid dialkyl ester [(1.0 equiv. (2g) or 2.0 equiv. (3d)] and (HO)( $^{i}PrO$ )P(O)CCl<sub>2</sub>P(O)(O $^{i}Pr$ )<sub>2</sub> or (MeO)<sub>2</sub>P(O)CCl<sub>2</sub>P(O)(OMe)(OH) were mixed in acetonitrile (3.0 ml). The mixture was stirred at room temperature for 21 h (3e) or heated at 50°C for 8 h (2g) or heated at 60°C for 15 h (3d). The mixture was filtered and the filtrate was evaporated to dryness in vacuo. After evaporation 2g was washed 6×20 ml hexane. The residue was diluted in 4.0 ml cold CH<sub>2</sub>Cl<sub>2</sub> and washed once with 1.0 ml cold saturated aq. NaCl (2g) or 1.0 ml cold saturated aq. NaHCO<sub>3</sub> (3d-e). A centrifuge was used to facilitate decantation. The organic phase was evaporated to dryness in vacuo. Compound 3d was further purified: 3d was dissolved in hexane by washing the residue several times with hexane (22 ml). The hexane phase was evaporated to dryness in vacuo.

**Potassium** *O*-dihexyloxyphosphoryl[(dimethoxyphosphoryl)dichloromethyl]phosphonate (2g). Prepared from (MeO)<sub>2</sub>P(O)CCl<sub>2</sub>P(O)(OMe)(OH) (147 mg) to give 2g (35 mg, 12%) as a white solid;  $\nu$  (KBr) 3367, 2945, 2499, 2239, 2072, 1031;  $\delta_{\rm H}$  (400.1 MHz, CD<sub>3</sub>OD) 4.18 (4H, m, CH<sub>2</sub>), 4.01 (6H, d, <sup>3</sup>*J*<sub>HP</sub>=10.8 Hz, OCH<sub>3</sub>), 1.72 (4H, m, CH<sub>2</sub>), 1.42 (4H, m, CH<sub>2</sub>), 1.30–1.35 (8H, m, CH<sub>2</sub>), 0.91 (6H, t, *J*=6.9 Hz, CH<sub>3</sub>);  $\delta_{\rm P}$  (162.0 MHz, CD<sub>3</sub>OD) 14.04 (d, <sup>2</sup>*J*<sub>PP'</sub>=24.3 Hz), -3.27 (t), -11.3 (d, <sup>2</sup>*J*<sub>P'P'</sub>=26.8 Hz);  $\delta_{\rm C}$  (100.6 MHz, CD<sub>3</sub>OD) 75.27 (dd, <sup>1</sup>*J*<sub>CP</sub>=149.8 Hz, <sup>1</sup>*J*<sub>CP</sub>=145.1 Hz), 69.50 (d, <sup>2</sup>*J*<sub>CP</sub>=6.4 Hz, CH<sub>2</sub>), 56.86 (d, <sup>2</sup>*J*<sub>CP</sub>=7.4 Hz, CH<sub>3</sub>), 32.08 (CH<sub>2</sub>), 30.81 (d, <sup>3</sup>*J*<sub>CP</sub>=7.5 Hz, CH<sub>2</sub>), 25.86 (CH<sub>2</sub>), 23.23 (CH<sub>2</sub>), 14.21 (CH<sub>3</sub>); ES–MS (C<sub>15</sub>H<sub>32</sub>Cl<sub>2</sub>O<sub>9</sub>P<sub>3</sub>) 519.5 *m*/*z* [M]<sup>-</sup>; HRMS: [MH<sub>2</sub>-K]<sup>+</sup>, found 521.0821. C<sub>15</sub>H<sub>34</sub>O<sub>9</sub>P<sub>3</sub>Cl<sub>2</sub> required 521.0793.

1-Methylethyl O-dimethoxyphosphoryl[(di-1-methylethoxyphosphoryl)dichloromethyl]phosphonate (**3d**). Prepared from (HO)(<sup>i</sup>PrO)P(O)CCl<sub>2</sub>P(O)(O<sup>i</sup>Pr)<sub>2</sub> (65 mg) to give 3d (40 mg, 48%) as yellowish oil; [Found: C, 28.34; H, 5.63. C<sub>12</sub>H<sub>27</sub>Cl<sub>2</sub>O<sub>9</sub>P<sub>3</sub>×H<sub>2</sub>O requires C, 28.99; H, 5.88%]; ν(KBr);δ<sub>H</sub> (400.1 MHz, CDCl<sub>3</sub>) 5.16 (1H, m, CH), 4.98 (2H, m, CH), 3.96 (3H, d,  ${}^{3}J_{HP}$ =12.1 Hz, CH<sub>3</sub>), 3.93 (3H, d,  ${}^{3}J_{\text{HP}}$ =12.0 Hz, CH<sub>3</sub>), 1.50 (3H, d, J=6.2 Hz, CH<sub>3</sub>), 1.48 (3H, d, J=6.2 Hz, CH<sub>3</sub>), 1.43 (6H, d, J=6.1 Hz, CH<sub>3</sub>), 1.42 (6H, d, J=5.9 Hz, CH<sub>3</sub>);  $\delta_P$  (162.0 MHz, CDCl<sub>3</sub>) 6.10 (d,  $^{2}J_{\text{PP}'}$ =25.6 Hz), -0.59 (dd), -10.78 (d,  $^{2}J_{\text{P}'\text{P}''}$ =29.7 Hz);  $\delta_{\text{C}}$  $(100.6 \text{ MHz}, \text{CDCl}_3)$  78.22 (d,  ${}^2J_{CP}$ =7.4 Hz, CH), 75.80 (d,  ${}^{2}J_{CP}$ =7.5 Hz, CH), 75.76 (d,  ${}^{2}J_{CP}$ =7.4 Hz, CH), 71.32 (dd,  ${}^{1}J_{CP}$ =166.6 Hz,  ${}^{1}J_{CP}$ =151.8 Hz), 55.60 (d,  ${}^{2}J_{CP}$ =7.5 Hz, CH<sub>3</sub>), 55.49 (d,  ${}^{2}J_{CP}$ =7.4 Hz, CH<sub>3</sub>), 24.33 (bs), 24.09 (d,  ${}^{3}J_{CP}=2.7$  Hz, CH<sub>3</sub>), 23.49 (bs); ES-MS (C<sub>12</sub>H<sub>28</sub>Cl<sub>2</sub>O<sub>9</sub>P<sub>3</sub>) 478.7 m/z [MH]<sup>+</sup>; HRMS: [M+Na]<sup>+</sup>, found 501.0139. C<sub>12</sub>H<sub>27</sub>O<sub>9</sub>P<sub>3</sub>Cl<sub>2</sub>Na required 501.0137.

**1-Methylethyl** *O*-methylsulphonyl[(di-1-methylethoxyphosphoryl)dichloromethyl]phosphonate (3e). Prepared from (HO)(<sup>i</sup>PrO)P(O)CCl<sub>2</sub>P(O)(O<sup>i</sup>Pr)<sub>2</sub> (119 mg) to give 3e (45 mg, 32%) as yellowish oil;  $\nu$ (KBr) 2986, 2248, 1379, 1284, 1193;  $\delta_{\rm H}$  (400.1 MHz, CDCl<sub>3</sub>) 5.20 (1H, m, CH), 4.98 (2H, m, CH), 3.45 (3H, s, SCH<sub>3</sub>), 1.51 (3H, d, *J*=6.2 Hz, CH<sub>3</sub>), 1.50 (3H, d, *J*=6.0 Hz, CH<sub>3</sub>), 1.43 (12H, d, *J*=6.0 Hz, CH<sub>3</sub>);  $\delta_{\rm P}$  (162.0 MHz, CDCl<sub>3</sub>) 5.61 (d, <sup>2</sup>*J*<sub>PP</sub>'=25.10), 0.66 (d);  $\delta_{\rm C}$  (100.6 MHz, CDCl<sub>3</sub>) 79.39 (d, <sup>2</sup>*J*<sub>CP</sub>=8.3 Hz, CH), 76.19 (d, <sup>2</sup>*J*<sub>CP</sub>=7.5 Hz, CH), 70.80 (dd, <sup>1</sup>*J*<sub>CP</sub>=164.3 Hz, <sup>1</sup>*J*<sub>CP</sub>=155.5 Hz), 40.97 (CH<sub>3</sub>), 24.36 (bs), 23.78 (d, <sup>3</sup>*J*<sub>CP</sub>=3.7 Hz, CH<sub>3</sub>), 23.44 (bs); ES-MS (C<sub>11</sub>H<sub>24</sub>Cl<sub>2</sub>O<sub>8</sub>P<sub>2</sub>S) 412.9 *m*/z [MH-Cl]<sup>+</sup>.

Disodium (O(P')-acetyl-O(P)-methyl)dichloromethylenebisphosphonate (4). The dealkylation of 9 was performed following the procedure described earlier<sup>25</sup> using 200 mg of 9, 300 µl water and 4.0 ml piperidine. After reaction, water and the excess of piperidine were evaporated to dryness in vacuo and acetic anhydride (3.0 ml) was added to the residue. The mixture was stirred at room temperature for 48 h and then kept in cold  $(+5^{\circ}C)$  overnight. The solids were collected and washed several times with cold acetone (14.0 ml), and dried in vacuo to give 4 (166 mg, 76%) as a white solid;  $\nu$ (KBr) 3540, 2970, 1725, 1638;  $\delta_{\rm H}$ (400.1 MHz, D<sub>2</sub>O) 3.78 (3H, d,  ${}^{3}J_{\rm HP}$ =10.4 Hz, CH<sub>3</sub>), 2.22  $(3H, d, {}^{4}J_{HP}=1.0 \text{ Hz}, CH_{3}); \delta_{P} (162.0 \text{ MHz}, D_{2}O) 9.08 (d,$  $^{2}J_{\text{PP}'}$ =16.1 Hz), 4.06 (d);  $\delta_{\text{C}}$  (100.6 MHz, D<sub>2</sub>O) 172.66 (d,  ${}^{2}J_{CP}=10.1$  Hz), 78.25 (dd,  ${}^{1}J_{CP}=146.6$  Hz,  ${}^{1}J_{CP}=138.4$  Hz), 57.91 (d,  ${}^{2}J_{CP}$ =4.2 Hz, CH<sub>3</sub>), 24.86 (d,  ${}^{3}J_{CP}$ =1.5 Hz, CH<sub>3</sub>); ES-MS ( $C_4H_7Cl_2O_7P_2$ ) 299.1 m/z [MH]<sup>+</sup>.

#### Acknowledgements

The elemental analyses were performed at the University of Joensuu, Finland. We would like to thank Mrs Maritta Salminkoski for skilful technical assistance.

#### References

- 1. Fleisch, H. Drugs 1991, 42, 919–944.
- 2. Yates, J. A.; Rodan, G. A. Drug Discov. Today 1998, 3, 69-78.
- 3. Socrates, E. P. Am. J. Med. 1993, 95, 48S-52S.
- 4. Giannini, S.; D'Angelo, A.; Sartori, L.; Passeri, G.; Carbonare,
- L. D.; Crepaldi, G. Obstet. Gynecol. 1996, 88, 431-436.

5. Fleisch, H. *Bisphosphonates in Bone Disease: From the Laboratory to the Patient*; The Parthenon Publishing Group Inc: New York, 1995.

- 6. Hamdy, N. A. T. Trends Endocrin. Met. 1993, 4, 19-25.
- 7. Lin, J. H. Bone 1996, 18, 75-85.

8. Fogelman, I.; Smith, L.; Mazess, R.; Wilson, M. A.; Bevan, J. A. *Clin. Endocrinol.* **1986**, *24*, 57–62.

9. Sloan, K. B. *Prodrugs: Topical and Ocular Drug Delivery*; Marcel Dekker: New York, 1992.

10. Krise, J. P.; Stella, V. J. Adv. Drug Deliv. Rev. **1996**, 19, 287-310.

11. Serafinowska, H. T.; Ashton, R. J.; Bailey, S.; Harnden, M. R.; Jackson, S. M.; Sutton, D. *J. Med. Chem.* **1995**, *38*, 1372–1379.

12. Dickson, J. K.; Biller, S. A.; Magnin, D. R.; Petrillo, E. W.;

Hillyer, J. W.; Hsieh, D. C.; Lan, S.-J.; Rinehart, J. K.; Gregg, R. E.; Harrity, T. W.; Jolibois, K. G.; Kalinowski, S. S.; Kunselman, L. K.; Mookhtiar, K. A.; Ciosek, C. P. J. Med. Chem. 1996, 39, 661–664.

- 13. Atack, J. R.; Prior, A. M.; Fletcher, S. R.; Quirk, K.; McKernan,
- R.; Ragan, C. I. J. Pharmacol. Exp. Ther. 1994, 270, 70-76.
- 14. McKenna, C. E.; Khawli, L. A.; Ahmad, W.-Y.; Pham, P.; Bongartz, J.-P. *Phosphorus Sulphur* **1988**, *37*, 1–12.
- 15. Vepsäläinen, J.; Pohjala, E.; Nupponen, H.; Vainiotalo, P.; Ahlgrèn, M. *Phosphorus, Sulphur, Silicon* **1992**, *70*, 183–203.
- 16. Vepsäläinen, J.; Kivikoski, J.; Ahlgrén, M.; Nupponen, H.; Pohjala, E. *Tetrahedron* **1995**, *51*, 6805–6818.
- 17. Vepsäläinen, J.; Vainiotalo, P.; Nupponen, H.; Pohjala, E. Acta Chem. Scand. **1997**, 51, 932–937.
- 18. Niemi, R.; Taipale, H.; Ahlmark, M.; Vepsäläinen, J.; Järvinen, T. J. Chromatogr. B **1997**, 701, 97–102.

- 19. Nielsen, N. M.; Bundgaard, H. Int. J. Pharm. 1987, 39, 75-85.
- 20. Friis, G. J.; Bundgaard, H. Eur. J. Pharm. Sci. 1996, 4, 49–59.
- 21. Ahlmark, M.; Niemi, R.; Taipale, H.; Vepsäläinen, J.; Järvinen, T. J. Med. Chem. **1999**, 42, 1473–1476.
- 22. Merck & Co. Inc. *Eur. Pat.* EP 0416689/1991, *Chem. Abstr.* 29628q.
- 23. Vepsäläinen, J.; Nupponen, H.; Pohjala, E. *Tetrahedron Lett.* **1996**, *37*, 3533–3536.
- 24. Muller, E. Methoden Der Organischen Chemie (Houben-Weyl); Georg Thieme Verlag: Stuttgart, 1964; Vol. 12/2, pp 286–290.
- 25. Ahlmark, M. J.; Vepsäläinen, J. J. *Tetrahedron* **1997**, *53*, 16153–16160.